Skip to main content
Erschienen in:

30.05.2023 | Insuline | Im Fokus

Diabetes Update 2023

Viel Neues in der Therapie

verfasst von: Univ.-Prof. Dr. med. Werner A. Scherbaum

Erschienen in: Die Diabetologie | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Auszug

Hier sollen einige der wichtigsten neuen Erkenntnisse auf dem Gebiet der Diabetologie wiedergegeben werden, welche beim Diabetes Update 2023 vorgestellt wurden. Bezüglich einer ausführlicheren Beschreibung neuer Studienergebnisse und deren Wertung durch die Referenten sei auf das Manual der Seminarunterlagen verwiesen [1]. Auf die Themen Typ-1-Diabetes, Herz und Lipide, Sport sowie interventionelle Angiologie wird von den entsprechenden Referenten in diesem Heft in separaten Artikeln eingegangen. …
Literatur
1.
Zurück zum Zitat Hamann A, Martin S, Stumvoll M (Hrsg) (2023) Update Diabetologie. Seminarunterlagen Diabetes Update Bd. 2023 – 18. Diabetologie-Update-Seminar, Mainz Hamann A, Martin S, Stumvoll M (Hrsg) (2023) Update Diabetologie. Seminarunterlagen Diabetes Update Bd. 2023 – 18. Diabetologie-Update-Seminar, Mainz
2.
Zurück zum Zitat Davies MJ et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65(12):1925–1966CrossRefPubMedPubMedCentral Davies MJ et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65(12):1925–1966CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat American Diabetes Association (2023) Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes—2023. Suppl.1, Bd. 46, S S140–S157 American Diabetes Association (2023) Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes—2023. Suppl.1, Bd. 46, S S140–S157
4.
Zurück zum Zitat Wang X, Cheng FTF, Lam TYT et al (2022) Stress hyperglycemia is associated with an increased risk of subsequent development of diabetes among bacteriemic and nonbacteriemic patients. Diabetes Care 45:1438–1444CrossRefPubMed Wang X, Cheng FTF, Lam TYT et al (2022) Stress hyperglycemia is associated with an increased risk of subsequent development of diabetes among bacteriemic and nonbacteriemic patients. Diabetes Care 45:1438–1444CrossRefPubMed
5.
Zurück zum Zitat Wang MT, Huang Y‑L, Lai J‑H et al (2022) Association between specificity of sulfonylureas to cardiac mitochondrial KATP channels and the risk of major adverse cardiovascular events in type 2 diabetes. Diabetes Care 45:1276–1287CrossRefPubMed Wang MT, Huang Y‑L, Lai J‑H et al (2022) Association between specificity of sulfonylureas to cardiac mitochondrial KATP channels and the risk of major adverse cardiovascular events in type 2 diabetes. Diabetes Care 45:1276–1287CrossRefPubMed
6.
Zurück zum Zitat Kivimäki M, Strandberg T, Pentti J et al (2022) Body-Mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol 10(4):253–263CrossRefPubMedPubMedCentral Kivimäki M, Strandberg T, Pentti J et al (2022) Body-Mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol 10(4):253–263CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Lee BJ, Yim MH (2021) Comparison of anthropometric and body composition indices in the identification of metabolic factors. Sci Rep 11(1):9931CrossRefPubMedPubMedCentral Lee BJ, Yim MH (2021) Comparison of anthropometric and body composition indices in the identification of metabolic factors. Sci Rep 11(1):9931CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Delago-Lista X, Alcala-Diaz JF, Torres-Peña JD et al (2022) Long-term secondary prevention of cardiovascular disease with a mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet 399:1876–1885CrossRef Delago-Lista X, Alcala-Diaz JF, Torres-Peña JD et al (2022) Long-term secondary prevention of cardiovascular disease with a mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet 399:1876–1885CrossRef
9.
Zurück zum Zitat Wimberley T, Horsdal HL, Brikell I et al (2022) Temporally ordered asociations between type 2 diabetes and brain disorders—a register-based cohort study. Bmc Psychiatry 22(1):573CrossRefPubMedPubMedCentral Wimberley T, Horsdal HL, Brikell I et al (2022) Temporally ordered asociations between type 2 diabetes and brain disorders—a register-based cohort study. Bmc Psychiatry 22(1):573CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Lake J, Bortolasci CC, Stuart AL et al (2023) Metformin is protective against the development of mood disorders. Pharmacopsychiatry 56(1):25–31CrossRefPubMed Lake J, Bortolasci CC, Stuart AL et al (2023) Metformin is protective against the development of mood disorders. Pharmacopsychiatry 56(1):25–31CrossRefPubMed
11.
Zurück zum Zitat Calkin CV et al (2022) Treating insulin resistance with metformin as a streategy to improve clinical outcomes in treatment-resistant bipolar depression (the TRIO-BD Study): A randomized, quadruple-masked, placebo-controlled clinical trail. J Clin Psychiatrs 83(2):21m14022. https://doi.org/10.4088/JCP.21m14022CrossRef Calkin CV et al (2022) Treating insulin resistance with metformin as a streategy to improve clinical outcomes in treatment-resistant bipolar depression (the TRIO-BD Study): A randomized, quadruple-masked, placebo-controlled clinical trail. J Clin Psychiatrs 83(2):21m14022. https://​doi.​org/​10.​4088/​JCP.​21m14022CrossRef
13.
Zurück zum Zitat Hallström S, Svensson A‑M, Pivodic A (2021) Risk factors and incidence over time for lower extremity amputations in people wit type 1 diabetes: an observational cohort study of 46088 patients from the Swedish Diabetes Registry. Diabetologia 64(12):2751–2761CrossRefPubMedPubMedCentral Hallström S, Svensson A‑M, Pivodic A (2021) Risk factors and incidence over time for lower extremity amputations in people wit type 1 diabetes: an observational cohort study of 46088 patients from the Swedish Diabetes Registry. Diabetologia 64(12):2751–2761CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Boyko EJ, Zelnick LR, Braffett BH et al (2022) Risk of foot ulcer and lower extremity amputation among participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 45(2):357–364CrossRefPubMedPubMedCentral Boyko EJ, Zelnick LR, Braffett BH et al (2022) Risk of foot ulcer and lower extremity amputation among participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 45(2):357–364CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Frykberg RG, Franks PJ, Edmonds M et al (2020) A multinational, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of cyclical topical wound oxygen (TWO2) therapy in the treatment of chronic diabetic foot ulcers. The TWO2 study. Diabetes Care 43(3):616–624CrossRefPubMed Frykberg RG, Franks PJ, Edmonds M et al (2020) A multinational, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of cyclical topical wound oxygen (TWO2) therapy in the treatment of chronic diabetic foot ulcers. The TWO2 study. Diabetes Care 43(3):616–624CrossRefPubMed
16.
Zurück zum Zitat Engels G (2022) Fußchirurgie beim diabetischen Fußulkus (DFS).Das Entitätenkonzept als Orientierungshilfe. Gefäßchirurgie 27:388–400CrossRef Engels G (2022) Fußchirurgie beim diabetischen Fußulkus (DFS).Das Entitätenkonzept als Orientierungshilfe. Gefäßchirurgie 27:388–400CrossRef
17.
Zurück zum Zitat Fioretto P, Pontremoli R (2022) Expanding the therapy options for diabetic kidney disease. Nat Rev Nephrol 18:78–79CrossRefPubMed Fioretto P, Pontremoli R (2022) Expanding the therapy options for diabetic kidney disease. Nat Rev Nephrol 18:78–79CrossRefPubMed
18.
Zurück zum Zitat Agarval R, Filippatos G, Pitt B et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease. The FIDELITY pooled analysis. Eur Heart J 43:474–484CrossRef Agarval R, Filippatos G, Pitt B et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease. The FIDELITY pooled analysis. Eur Heart J 43:474–484CrossRef
19.
Zurück zum Zitat Bakris GL, Ruilope LM, Anker SD et al (2022) A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int 103(1):196–206CrossRefPubMed Bakris GL, Ruilope LM, Anker SD et al (2022) A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int 103(1):196–206CrossRefPubMed
20.
Zurück zum Zitat Merino J, Guasch-Ferré M, Li J et al (2022) Polygenic scores, diet quality, and type 2 diabetes risk: An observational study among 35.759madults from 3 US cohorts. PLoS Med 19(4):e1003972CrossRefPubMedPubMedCentral Merino J, Guasch-Ferré M, Li J et al (2022) Polygenic scores, diet quality, and type 2 diabetes risk: An observational study among 35.759madults from 3 US cohorts. PLoS Med 19(4):e1003972CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Debras C, Chazelas E, Sellem L et al (2022) Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort. BMJ 378:e071204 Debras C, Chazelas E, Sellem L et al (2022) Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort. BMJ 378:e071204
23.
Zurück zum Zitat Mathiesen ER, Alibegovic AC, Corcoy R et al (2023) Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, controlled, non-inferiority trial. Lancet Diabetes Endocrinol 11(2):86–95CrossRefPubMed Mathiesen ER, Alibegovic AC, Corcoy R et al (2023) Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, controlled, non-inferiority trial. Lancet Diabetes Endocrinol 11(2):86–95CrossRefPubMed
24.
Zurück zum Zitat Crowther CA, Samuel D, McCowan LME et al (2022) Lower versus higher glycemic criteria of gestational diabetes. N Engl J Med 387:587–598CrossRefPubMed Crowther CA, Samuel D, McCowan LME et al (2022) Lower versus higher glycemic criteria of gestational diabetes. N Engl J Med 387:587–598CrossRefPubMed
25.
Zurück zum Zitat Feig DS et al (2022) Determinants of small for gestational age in women with type 2 diabetes in pregnancy: Who should receive metformin? Diabetes Care 45(7):1532–1539CrossRefPubMed Feig DS et al (2022) Determinants of small for gestational age in women with type 2 diabetes in pregnancy: Who should receive metformin? Diabetes Care 45(7):1532–1539CrossRefPubMed
28.
Zurück zum Zitat Chan CC, Tse YK, Liu RNS (2022) Fatty pancreas is independently associated with subsequent diabetes mellitus development. A 10-year prospective cohort study. Clin Gastroenterol Hepatol 20(9):2014–2022.e4CrossRefPubMed Chan CC, Tse YK, Liu RNS (2022) Fatty pancreas is independently associated with subsequent diabetes mellitus development. A 10-year prospective cohort study. Clin Gastroenterol Hepatol 20(9):2014–2022.e4CrossRefPubMed
29.
Zurück zum Zitat Al Mrabeh A, Hollingsworth GK, Shaw JAM et al (2020) 2‑year remission of type 2 diabetes and pancreas morphology: A post-hoc analysis of the DIRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 8(12):939–948CrossRefPubMed Al Mrabeh A, Hollingsworth GK, Shaw JAM et al (2020) 2‑year remission of type 2 diabetes and pancreas morphology: A post-hoc analysis of the DIRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 8(12):939–948CrossRefPubMed
30.
Zurück zum Zitat Wensink MJ, Lu YT et al (2022) Preconception antidiabetic drugs in men and birth defects in offspring. A nationwide cohort study. Ann Intern Med 175:665–673CrossRefPubMedPubMedCentral Wensink MJ, Lu YT et al (2022) Preconception antidiabetic drugs in men and birth defects in offspring. A nationwide cohort study. Ann Intern Med 175:665–673CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Biondi B, Cappola AR (2022) Subclinical hypothyroidism in older individuals. Lancet 10(2):120–141 Biondi B, Cappola AR (2022) Subclinical hypothyroidism in older individuals. Lancet 10(2):120–141
32.
Zurück zum Zitat Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: A narrative review. Adv Ther 39:58–74CrossRefPubMed Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: A narrative review. Adv Ther 39:58–74CrossRefPubMed
33.
Zurück zum Zitat Cosman F, Kendler D, Langdahl BL et al (2022) Romosozumab and antiresorptive treatment: The importance of treatment sequence. Osteoporos Int 33:1243–1256CrossRefPubMedPubMedCentral Cosman F, Kendler D, Langdahl BL et al (2022) Romosozumab and antiresorptive treatment: The importance of treatment sequence. Osteoporos Int 33:1243–1256CrossRefPubMedPubMedCentral
Metadaten
Titel
Diabetes Update 2023
Viel Neues in der Therapie
verfasst von
Univ.-Prof. Dr. med. Werner A. Scherbaum
Publikationsdatum
30.05.2023
Verlag
Springer Medizin
Erschienen in
Die Diabetologie / Ausgabe 4/2023
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI
https://doi.org/10.1007/s11428-023-01054-z

Weitere Artikel der Ausgabe 4/2023

Die Diabetologie 4/2023 Zur Ausgabe

Einführung zum Thema

Diabetes Update 2023

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.